ArticleReports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology2026
Long-term pulmonary function decline after stereotactic body radiation therapy for lung tumors.
Article in Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Stereotactic body radiation therapy (SBRT) is widely used for early-stage lung cancer and inoperable cases due to its high local control rate and limited invasiveness. However, its long-term impact on pulmonary function remains controversial. Materials and methods: We retrospectively analyzed patients with lung tumors who underwent SBRT at our institution between November 2009 and May 2024 and had at least one pulmonary function test (PFT) before and after treatment. Patients with prior thoracic radiotherapy or post-treatment events affecting lung function were excluded. PFT changes were assessed at multiple post-treatment intervals. Lung dose parameters and correlations with changes in PFT results were analyzed. Receiver operating characteristic (ROC) analysis was used to determine dose cut-off values predictive of a ≥ 10% decline in pulmonary function. Results: A total of 61 patients were included. Significant declines in vital capacity (VC), forced vital capacity (FVC), and forced expiratory volume in 1 second (FEV Conclusions: Pulmonary function decline after SBRT becomes evident more than 2 years post-treatment and is associated with specific lung dose parameters. These findings highlight the importance of long-term monitoring and careful dose planning in SBRT for lung tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.